Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine,
GEN-009, that is being developed for the treatment of patients with solid tumors. A
proprietary tool developed by Genocea, called ATLAS™ (Antigen Lead Acquisition System) will
be used to identify neoantigens in each patient's tumor that are recognized by their CD4
and/or CD8 T cells. ATLAS-identified neoantigens will then be incorporated into a patient's
personalized vaccine in the form of synthetic long peptides (SLPs).